Back to top

The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Novartis, Johnson & Johnson, Bayer and Shire

Read MoreHide Full Article

For Immediate Release

Chicago, IL – October 22, 2012 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Watson Pharmaceuticals, Inc. , Novartis (NVS - Free Report) , Johnson & Johnson (JNJ - Free Report) , Bayer (BAYRY - Free Report) and Shire (SHPG - Free Report) .

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter:


Here are highlights from Friday’s Analyst Blog:


Watson a Step Closer to Actavis

Watson Pharmaceuticals, Inc. recently received a favorable vote from the Federal Trade Commission (FTC) for its proposed acquisition of the Actavis group of companies. However, Watson Pharma will be required to sell certain products.

These products will be sold to Par Pharmaceuticals, Inc. and Novartis’ (NVS - Free Report) generic division, Sandoz. Currently marketed products that will be sold to Par Pharma include Actavis' generic versions of Johnson & Johnson’s (JNJ - Free Report) fentanyl transdermal film (chronic pain), Ani Pharmaceuticals, Inc.’s Reglan (nausea), Kadian (acute pain), and Bayer’s (BAYRY - Free Report) Adalat CC (hypertension and angina) among others.

Moreover, Par Pharma will acquire Watson’s pending applications for its generic versions of several products including Shire’s (SHPG - Free Report) Adderall XR (attention deficit hyperactivity disorder), among others.

All total, Watson Pharma and Actavis will be selling the rights and assets to 18 drugs and the manufacturing rights to three more.

EC Approval Already Gained

The FTC vote comes a few days after Watson Pharma received the green signal from the European Commission (EC) for its proposed acquisition of Actavis. The EC said that although the acquisition will lead to major changes in the competitive scenario, the combined entity will, nevertheless, continue facing strong competition.

The EC focused on the impact of the acquisition on the markets for drugs like anti-depressants and anti-hypertensives, especially in Denmark, Sweden and the UK.

Acquisition a Smart Strategic Move

Watson Pharma had first announced its intention to acquire Actavis in April 2012 for an upfront payment of €4.25 billion. Actavis stakeholders could also receive an additional consideration depending on the achievement of certain 2012 performance targets. The achievement of these targets would result in the delivery of up to 5.5 million shares of Watson Pharma in 2013. Actavis has a presence in more than 40 countries. The acquisition is slated to close later this month/early next month.

We view the upcoming acquisition of Actavis as a smart strategic move by Watson Pharma. This deal, which is expected to be immediately accretive, should help the company strengthen its presence in the ex-US generics market and expand and strengthen its presence and product portfolio. The acquisition will more than double the company’s commercial position in key European markets as well as emerging markets, including Central and Eastern Europe and Russia.

We note that this acquisition will make Watson Pharma the third largest global generics company. We currently have a Neutral recommendation on Watson Pharma, which carries a Zacks #2 Rank (short-term ‘Buy’ rating).

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter:

About Zacks Equity Research                                                                              

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today:

About Zacks is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at

Visit for information about the performance numbers displayed in this press release.

Follow us on Twitter:

Join us on Facebook:

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

Media Contact
Zacks Investment Research

800-767-3771 ext. 9339


In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Novartis AG (NVS) - free report >>

Johnson & Johnson (JNJ) - free report >>

Bayer AG (BAYRY) - free report >>

Shire PLC (SHPG) - free report >>

More from Zacks Press Releases

You May Like